U.S. Markets closed
  • S&P 500

    4,232.60
    +30.98 (+0.74%)
     
  • Dow 30

    34,777.76
    +229.23 (+0.66%)
     
  • Nasdaq

    13,752.24
    +119.39 (+0.88%)
     
  • Russell 2000

    2,271.63
    +30.21 (+1.35%)
     
  • Crude Oil

    64.82
    +0.11 (+0.17%)
     
  • Gold

    1,832.00
    +16.30 (+0.90%)
     
  • Silver

    27.57
    +0.10 (+0.38%)
     
  • EUR/USD

    1.2168
    +0.0100 (+0.8275%)
     
  • 10-Yr Bond

    1.5770
    +0.0160 (+1.02%)
     
  • Vix

    16.69
    -1.70 (-9.24%)
     
  • GBP/USD

    1.3990
    +0.0097 (+0.6995%)
     
  • USD/JPY

    108.5820
    -0.5030 (-0.4611%)
     
  • BTC-USD

    57,922.64
    +2,073.97 (+3.71%)
     
  • CMC Crypto 200

    1,480.07
    +44.28 (+3.08%)
     
  • FTSE 100

    7,129.71
    +53.54 (+0.76%)
     
  • Nikkei 225

    29,357.82
    +26.45 (+0.09%)
     

Immunic's IMU-838 Shows Promising Clinical Effect In Mid-Stage Liver Disease Study

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Immunic Inc (NASDAQ: IMUX) has announced top-line data from an investigator-sponsored Phase 2 proof-of-concept trial evaluating IMU-838 in primary sclerosing cholangitis (PSC), a rare liver disease characterized by inflamed and narrow bile ducts, thus preventing bile from flowing correctly.

  • 27.3% of the patients in the per-protocol population had a clinically relevant reduction of serum alkaline phosphatase higher than 25% at week 24, without an increase in liver biochemistry of more than 33%, as compared to baseline.

  • Regarding the secondary objectives of the study, no changes in aspartate aminotransferase, alanine aminotransferase, or total, direct or indirect bilirubin were observed compared to baseline.

  • The study also found that IMU-838 is safe and well-tolerated.

  • Yesterday, the company announced IMU-838 data from 204 COVID-19 patients who showed clinical activity evidence compared to placebo.

  • IMU-838 is an oral selective immune modulator that inhibits activated immune cells' intracellular metabolism by blocking the enzyme dihydroorotate dehydrogenase (DHODH).

  • Immunic's management team will host a conference call and webcast today at 8:00 a.m. ET.

  • Price Action: IMUX shares are up by 3.99% at $21.10 in the premarket session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.